PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 ...

Shares of Viatris Inc. VTRS slid 1.87% to $8.92 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.13% to 5,976.97 and Dow ...

Shares of Viatris Inc. VTRS rallied 2.61% to $9.04 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 6,038.81 and ...

Viatris Inc. (NASDAQ:VTRS), a prominent player in the biopharmaceutical industry with a market capitalization of $9.73 billion, finds itself navigating a complex landscape of challenges and ...

On Thursday, 05 June 2025, Viatris Inc. (NASDAQ:VTRS) presented at the Jefferies Global Healthcare Conference 2025, highlighting its strategic execution and growth outlook. The company reported ...

Great. Well, thank you, everyone, for joining us. We're very pleased to have Viatris today. And with us, we have Scott Smith, CEO; Theodora Mistras, Chief Financial Officer; Corinne Le Goff ...

As of June 3, 2025, the average one-year price target for Viatris is €9.76/share. The forecasts range from a low of €7.15 to a high of €12.17. The average price target represents an increase ...

LYNX-2 patients will continue to be monitored for long-term safety over 48 weeks. Viatris Chief R&D Officer Philippe Martin said, "Our eye care pipeline is designed to address a broad range of ...

Link: https://www.zacks.com/commentary/2490523/3-generic-drug-stocks-to-watch-amid-pricing-pressure-tariff-threats Generic drugmakers continue to face mounting ...